Mode
Text Size
Log in / Sign up
N/A N=72 Randomized Double-blind Treatment

Daily Disposable Dispensing Clinical Trial of Test Lens Against Stenfilcon A Lens

Myopia

Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Subjective Ratings on Comfort — 9.7; 9.6 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
stenfilcon A lens with solution additive (test) (Device); stenfilcon A lens (control) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
CooperVision, Inc.
Primary completion
Apr 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Subjective Ratings on Comfort
8.9; 8.6
PRIMARY
Subjective Ratings on Comfort
8.9; 8.6
PRIMARY
Subjective Ratings on Comfort
8.9; 8.6
PRIMARY
Vision Satisfaction
3; 1; 1; 3; 4; 9
PRIMARY
Vision Satisfaction
3; 1; 1; 3; 4; 9
PRIMARY
Vision Satisfaction
3; 1; 1; 3; 4; 9
PRIMARY
Visual Acuity On High Illumination High Contrast
-0.21; -0.20
PRIMARY
Visual Acuity On High Illumination High Contrast
-0.21; -0.20
PRIMARY
Visual Acuity On High Illumination High Contrast
-0.21; -0.20
PRIMARY
Visual Acuity On Low Illumination High Contrast
-0.09; -0.09
PRIMARY
Visual Acuity On Low Illumination High Contrast
-0.09; -0.09
PRIMARY
Visual Acuity On Low Illumination High Contrast
-0.09; -0.09
PRIMARY
Overall Corneal Staining
54; 58; 33; 30; 13; 11
PRIMARY
Overall Corneal Staining
54; 58; 33; 30; 13; 11
PRIMARY
Conjunctival Staining
0.42; 0.45
PRIMARY
Conjunctival Staining
0.42; 0.45
PRIMARY
Bulbar Hyperemia
1.36; 1.33
PRIMARY
Bulbar Hyperemia
1.36; 1.33
PRIMARY
Limbal Hyperemia
0.90; 0.78
PRIMARY
Limbal Hyperemia
0.90; 0.78
PRIMARY
Palpebral Hyperemia
1.02; 0.93
PRIMARY
Palpebral Hyperemia
1.02; 0.93
SECONDARY
Lens Fit Acceptance
3.3; 3.2
SECONDARY
Lens Fit Acceptance
3.3; 3.2
SECONDARY
Lens Fit Acceptance
3.3; 3.2
SECONDARY
Handling Satisfaction
0; 1; 0; 4; 1; 0
SECONDARY
Handling Satisfaction
0; 1; 0; 4; 1; 0
SECONDARY
Lens Surface - Wettability
3.37; 3.38
SECONDARY
Lens Surface - Wettability
3.37; 3.38
SECONDARY
Lens Surface - Wettability
3.37; 3.38
SECONDARY
Lens Surface - Deposits
0.06; 0.02
SECONDARY
Lens Surface - Deposits
0.06; 0.02
SECONDARY
Lens Surface - Deposits
0.06; 0.02
SECONDARY
Subjective Ratings on Dryness
8.3; 8.1
SECONDARY
Subjective Ratings on Dryness
8.3; 8.1
SECONDARY
Subjective Ratings on Dryness
8.3; 8.1

Summary

The purpose of this study is to investigate the overall clinical performance of the test daily disposable stenfilcon A lens with solution additive (test) compared to the stenfilcon A lens (control).

Eligibility Criteria

Inclusion Criteria

  • A person is eligible for inclusion in the study if he/she:
  • Has had a self-reported oculo-visual examination in the last two years.
  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Has read and understood the information consent letter.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best-corrected.
  • Must achieve 20/30 or better (in each eye) with study lenses
  • Requires spectacle lens powers between -0.75 and -6.50 diopters sphere (0.25D steps).
  • Has no more than 0.75 diopters of refractive astigmatism.
  • Currently wears soft contact lenses.
  • Have clear corneas and no active ocular disease.
  • Has not worn lenses for at least 12 hours before the examination

Exclusion Criteria

  • A person will be excluded from the study if he/she:
  • Has never worn contact lenses before.
  • Has any systemic disease affecting ocular health.
  • Is using any systemic or topical medications that will affect ocular health.
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses.
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.
  • Is aphakic.
  • Has undergone corneal refractive surgery.
  • Is pregnant, lactating, or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit).
  • Have taken part in any other contact lens or care solution clinical trial or research, within one week prior to starting this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03024970). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search